Clinical Trials Logo

Clinical Trial Summary

This study will examine the effectiveness of the drug propranolol in preventing fainting in patients with sympathoadrenal imbalance (SAI). SAI is a particular pattern of nervous system and chemical responses in which the blood vessels in skeletal muscles do not remain constricted appropriately during standing for a long time. This can lower blood pressure and cause fainting. Propranolol (Inderal® (Registered Trademark)) is a Food and Drug Administration-approved drug that belongs to a class of drugs called beta-blockers. These drugs slow the heart rate and maintain blood pressure in certain situations.

Children between 10 and 17 years of age with frequent fainting or near-fainting due to SAI may be eligible for this study. Children must experience severe dizzy episodes at least once every 2 months or fainting episodes at least once every 4 months. The condition must be severe enough to affect the child's quality of life or to have forced the child to alter his or her life routines to accommodate to the illness. Screening includes a tilt table test, described below, to determine if the child has a particular chemical pattern in the blood.

Children enrolled in the study take propranolol pills in increasing doses during the first week of the study to determine the proper dose for the individual. Then, the drug is stopped until the experimental phase of the study begins. In this phase, children are randomly assigned to take either propranolol or placebo (a look-alike pill with no active ingredient) for a maximum of 3 days. On the fourth day, the child undergoes a tilt table test to determine whether the treatment affects his or her ability to tolerate tilt. For this test, the child lies on a padded table with a motorized tilt mechanism that can move the child from a flat position to an upright position in about 10 seconds. The child remains upright for up to 40 minutes while the following measurements are taken:

- Blood sampling: Blood is drawn through a catheter (thin plastic tube) placed in an arm vein. This allows repeated sampling without repeated needle sticks. Samples are collected before starting the tilt test, about every 4 minutes during the test, immediately when a drop in blood pressure is detected or symptoms develop, and after 10 minutes of recovery lying flat. A maximum of 12 samples are collected for each tilt test.

- Physiologic measurements: Blood pressure, heart rate, and electrocardiogram (EKG) are measured continuously during the tilt test session, and blood flows and skin electrical conduction are measured intermittently. Blood flow is measured using sensors applied to the skin and a blood pressure cuff around the limb. For skin blood flow measurements, a laser beam scans the skin surface. The skin electrical conduction test measures how well the skin conducts electricity. This is measured through sensors placed on the tips of two fingers. Respiration and breathing rate are monitored by an elastic cloth band around the chest.

- Self-report questionnaires: Patients or their parents complete a questionnaire about the child's symptoms before and during treatment.

The effects of the test drug are allowed to wear off for up to 1 week, after which the entire tilt test procedure is repeated. Patients who were given propranolol for the first test session take placebo for the repeat session, and those who were given placebo take propranolol.


Clinical Trial Description

Objectives: This protocol is to evaluate treatment with oral propranolol for a particular form of neurocardiogenic syncope (NCS), characterized by a neuroendocrine pattern called "sympathoadrenal imbalance" (SAI), in children. In SAI, plasma adrenaline levels increase progressively and to a greater extent than do norepinephrine levels, before syncope. The SAI pattern is associated with skeletal muscle vasodilation. We hypothesize that increased occupation of beta-2 adrenoceptors in skeletal muscle by high circulating adrenaline levels precipitates the neurocirculatory positive feedback loop that leads to NCS.

Study Population: Patients 10-17 years old with a history of NCS.

Design: In a randomized, crossover-design, placebo-controlled, double-blind trial, we test the above hypothesis by using the non-selective beta-adrenoceptor blocker, propranolol. We predict that in patients with previously documented SAI and tilt-evoked NCS, propranolol treatment will improve orthostatic tolerance during follow-up tilt table testing.

Outcome Measures: The primary outcome measure will be whether propranolol therapy can prevent tilt induced syncope; or significant hypotension and/or bradycardia preceding development of clinical symptoms (greater than or equal to 20 mm Hg decrease in blood pressure or heart rate less than 40 beats/min). Secondary dependent measures that will be assessed are occurrence of duration of tilt tolerance (if tilt induced symptoms are provoked), hemodynamic and neurochemical indices of SAI, and patient questionnaire reports. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00093860
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase Phase 2
Start date October 2004
Completion date March 2005

See also
  Status Clinical Trial Phase
Completed NCT06038708 - Head-up Tilt Test in Patients With Reflex Syncope and Asystolic Response Who Received a Dual-chamber Pacemaker With the Closed Loop Stimulation (CLS) and Participated in the BIOSync Trial
Completed NCT00069693 - Evaluation of Chronic Orthostatic Intolerance N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT02565238 - BIO.MASTER.BioMonitor 2 Study N/A
Active, not recruiting NCT01965899 - Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System N/A
Completed NCT00746564 - Study of New Implantable Loop Recorder N/A
Completed NCT00359203 - ISSUE3: International Study on Syncope of Uncertain Etiology 3 Phase 4
Recruiting NCT04972071 - SW-RCT Implementation of Canadian Syncope Risk Score Based Practice Recommendations N/A
Completed NCT04198220 - BIO|STREAM.ICM Obesity
Recruiting NCT04533425 - Practical Approaches to Care in Emergency Syncope
Completed NCT05571254 - The Management of Transient Loss of Consciousness and Suspected Syncope in European Emergency Departments
Recruiting NCT05621460 - The Effect of Water Carbonation on Orthostatic Tolerance N/A
Not yet recruiting NCT05957315 - Mobile Cardiac Outpatient Telemetry for Unexplained Syncope N/A
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed NCT05729724 - Effect of Pharmacological Interventions on Systolic Blood Pressure Drops (SynABPM 2 Proof-of-concept)
Completed NCT05782712 - Rapid Measurement of Adenosine in Syncope Patients
Completed NCT03786640 - Abbott Brady 3T MRI PMCF
Recruiting NCT03803969 - ConfirmRxTM: Posture and Activity N/A
Recruiting NCT05575934 - Management of Transitory Loss of Consciousness and Syncopes in the Emergency Department
Recruiting NCT04075084 - Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)